Fate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Fate Therapeutics

28/02/2023 22:02

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended in December.
The mean expectation of twenty four analysts for the quarter was
for a loss of 86 cents per share.
    * Revenue rose 159.9% to $44.36 million from a year ago;
analysts
expected $16.72 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 58 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Fate Therapeutics Inc shares had fallen by 40.4% this
quarter.
    * The company reported a quarterly loss of $56.36 million.
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $8.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 15
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.86          -0.58          Beat
 Sep. 30 2022      -0.89          -0.86          Beat
 Jun. 30 2022      -0.83          -0.79          Beat
 Mar. 31 2022      -0.77          -0.68          Beat